Emergex has entered into an agreement with DEKA Research & Development (‘DEKA’) to assess the compatibility of Emergex’s T cell-priming set-point immunotherapeutic candidates with DEKA’s Intradermal Therapeutic Applicator. The collaboration
Coxsackievirus Treatment MarketThe global coxsackievirus infections treatment market is currently valued at US$ 5.5 Billion in 2023 and is anticipated to expand at a CAGR of 8.2%. Owing to the technological advances in healthcare the market is likely to propel to US$ 12.1 Billion by 2033.Major factors driving the gl.
Emergex and Brazil’s IBMP to co-fund Phase II and Phase III studies of Emergex’s Dengue Fever and Betacoronavirus T cell-priming immune set-point therapeutic